Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 2 | Orphanet Journal of Rare Diseases

Fig. 2

From: Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers

Fig. 2

Rates of bevacizumab adverse effects (such as hypertension, proteinuria, or poor wound healing) and discontinuation reported by HHT centers. Bar color represents response selected by respondent (e.g. 10–19% of patients treated at their center had an adverse event) and bar height reports the number of centers responding with that category for a given question. One center that reported treating 2 patients reported that both had treatment discontinued for lack of response (not shown in figure)

Back to article page